venBio Global Strategic Fund IV, L.P.
10% Owner
FundBuying only
- 2026
- Aug 10, 2026
- 1
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies venBio Global Strategic Fund IV, L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- GOLDMAN SACHS GROUP INC - $27.32M in ATTO purchases and sales in the last 12 months
- Colin Walsh - $27.32M in ATTO purchases and sales in the last 12 months
- Redmile Group, LLC - $10.20M in ATTO purchases and sales in the last 12 months
- Frazier Life Sciences XI, L.P. - $10.00M in ATTO purchases and sales in the last 12 months
- Sanofi - $5.10M in ATTO purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is venBio Global Strategic Fund IV, L.P.?
venBio Global Strategic Fund IV, L.P. is an investment firm, tracked as 10% Owner of Attovia Therapeutics, Inc. (ATTO). InsiderAlpha holds 1 primary Form 4 filing for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has venBio Global Strategic Fund IV, L.P. submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has venBio Global Strategic Fund IV, L.P. been buying or selling stock?
Recorded transactions: 1 open-market purchase ($6.50M) and 0 open-market sales across all tracked filings.
